Augmented antitumor effects of combination therapy of cisplatin with ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivo Qiang TanJing LiHui-hui Zeng PRECLINICAL STUDIES 07 March 2009 Pages: 205 - 215
Regulation of cell growth through cell cycle arrest and apoptosis in HPV 16 positive human cervical cancer cells by tea polyphenols Madhulika SinghShilpa TyagiYogeshwer Shukla PRECLINICAL STUDIES 07 March 2009 Pages: 216 - 224
Silibinin ameliorates oxidative stress induced aberrant crypt foci and lipid peroxidation in 1, 2 dimethylhydrazine induced rat colon cancer Nagarajan SangeethaSelvaraj AranganathanNamasivayam Nalini PRECLINICAL STUDIES 10 March 2009 Pages: 225 - 233
FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer Feng WangScharri J. EzellRuiwen Zhang PRECLINICAL STUDIES 10 March 2009 Pages: 234 - 241
Ongoing DNA synthesis in the rat cerebral cortex is regulated by a proteolytic pathway independent of the proteasome and calpains J. Sebastián YakisichÅke SidénMabel Cruz PRECLINICAL STUDIES 17 March 2009 Pages: 242 - 250
Chemopreventive efficacy of gallic acid, an antioxidant and anticarcinogenic polyphenol, against 1,2-dimethyl hydrazine induced rat colon carcinogenesis Jebakkan Senapathy GiftsonSathiavelu JayanthiNamasivayam Nalini PRECLINICAL STUDIES 20 March 2009 Pages: 251 - 259
Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD) Robert T. O’DonnellShiloh M. MartinJoseph M. Tuscano PRECLINICAL STUDIES Open access 24 March 2009 Pages: 260 - 267
Screening of a PKC ζ-specific kinase inhibitor PKCzI257.3 which inhibits EGF-induced breast cancer cell chemotaxis Jing WuBaogang ZhangNing Zhang PRECLINICAL STUDIES 27 March 2009 Pages: 268 - 275
The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy K. DredgeE. HammondI. Bytheway PRECLINICAL STUDIES 09 April 2009 Pages: 276 - 283
Suppression of in vivo tumor growth by using a biodegradable thermosensitive hydrogel polymer containing chemotherapeutic agent Mi Kyung KwakKeun HurHan-Kwang Yang PRECLINICAL STUDIES 22 April 2009 Pages: 284 - 290
Synthesis and in vitro characterization of ionone-based chalcones as novel antiandrogens effective against multiple clinically relevant androgen receptor mutants Jinming ZhouGuoyan GengJian Hui Wu PRECLINICAL STUDIES 24 April 2009 Pages: 291 - 298
Strong inhibition of replicative DNA synthesis in the developing rat cerebral cortex and glioma cells by roscovitine Juan Sebastian YakisichMarina Fernanda VitaMabel Cruz PRECLINICAL STUDIES 24 April 2009 Pages: 299 - 305
Possible contribution of β-glycosidases and caspases in the cytotoxicity of novel glycoconjugates in colon cancer cells Hossam M. M. Arafa PRECLINICAL STUDIES 05 May 2009 Pages: 306 - 317
MMPT: a thiazolidin compound inhibits the growth of lung cancer H1792 cells via Fas-mediated and caspase-dependent apoptosis pathway Yun-feng ZhaoXiu-lan LiQing-Zhong Kong PRECLINICAL STUDIES 06 May 2009 Pages: 318 - 325
Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response Brigette B.Y. MaVivian W.Y. LuiAnthony T.C. Chan PRECLINICAL STUDIES Open access 16 September 2009 Pages: 326 - 333
Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer Jan C. BucknerBahram ForouzeshEric K. Rowinsky PHASE I STUDIES 05 May 2009 Pages: 334 - 342
Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer Sung Yong OhHyun Jin KimJung Hun Kang PHASE II STUDIES 15 May 2009 Pages: 343 - 349
Acute left ventricular dysfunction induced by a panHER and VEGFR tyrosine kinase inhibitor in a phase I trial Rastislav BahledaChristophe MassardStéphane Ederhy SHORT REPORT 25 April 2009 Pages: 350 - 352
Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience Derek G. PowerManish A. ShahNancy E. Kemeny REVIEW 26 May 2009 Pages: 353 - 360
Erratum to: Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response Brigette B. Y. MaVivian W. Y. LuiAnthony T. C. Chan Erratum Open access 15 February 2010 Pages: 361 - 361